Salidroside Attenuates High-Altitude Hypoxic Myocardial Injury Through Modulation of Oxidative Stress and AKT/GSK-3β Signaling Pathways Authors: Danzeng Awang, Zong La, Kangzhuo Baima, Hongjun Xie, Li Wang, Xinyao Liu, Yueying Wang, Yan Shi, Yicheng Zhao, Lanzi Gongga Published: 2026 ABSTRACT AbstractHypoxia-related myocardial injury is characterized by oxidative stress, mitochondrial dysfunction, and apoptosis, ultimately resulting in impaired cardiac structure and function. Salidroside (SAL), a major bioactive component of Rhodiola, has been shown to have antioxidant and cardioprotective effects, but its role in hypoxia-related myocardial injury remains incompletely understood. In this study, we combined network pharmacology, molecular docking, and experimental validation to investigate the protective effect of SAL in CoCl2-induced hypoxia-mimetic models. In vitro, SAL improved cell viability, reduced ROS accumulation, restored mitochondrial membrane potential and ATP production, and attenuated apoptosis in CoCl2-treated H9C2 cells. In vivo, SAL alleviated electrocardiographic abnormalities, myocardial histopathological injury, cardiomyocyte hypertrophy, and associated lung and liver damage in CoCl2-treated rats. Mechanistically, SAL modulated the Akt/GSK-3β signaling axis under CoCl2-induced stress. Notably, Akt inhibition experiments revealed that SAL promotes protective GSK-3β phosphorylation and exerts its anti-apoptotic effects through a largely Akt-independent mechanism. Collectively, these findings indicate that SAL alleviates hypoxia-induced myocardial injury through the attenuation of oxidative stress, the preservation of mitochondrial function, the suppression of apoptosis, and the robust, Akt-independent regulation of GSK-3β.Graphical Abstract Keywords: Hypoxia-mimetic myocardial injury, Salidroside, Oxidative stress, Mitochondrial dysfunction, Akt/GSK-3β signaling axis Introduction High-altitude hypoxia is a major stressor encountered by people living at high elevations and can lead to both acute and chronic hypoxic damage, including high-altitude pulmonary edema, high-altitude heart disease, and high-altitude cerebral injury [1–3]. The heart, a highly oxygen-dependent organ, relies on a continuous supply of oxygen to maintain myocardial cell vitality and normal function [4]. Prolonged exposure to hypoxic environments results in a persistent decline in oxygen partial pressure, reducing the oxygen supply to cardiomyocytes, which affects myocardial energy production [5, 6]. This decrease in oxygen availability induces the production and accumulation of reactive oxygen species (ROS), leading to myocardial dysfunction, impaired contractility, and even apoptosis and myocardial necrosis [7]. With the increasing popularity of high-altitude tourism and the growing demands for national defense, more individuals are traveling from lowland areas to high-altitude regions. Consequently, understanding the mechanisms of hypoxia-induced cardiac injury and exploring effective prevention strategies have become critical research priorities. In clinical practice, medications such as dexamethasone and nimodipine are widely used to treat hypoxia-related high-altitude diseases [8, 9]. Although these drugs offer some relief, their use is limited because of significant adverse effects. Traditional Chinese medicine (TCM) offers promising alternatives, including herbs such as Eleutherococcus senticosus, Rhodiola rosea, and Panax ginseng [10, 11]. Among these, the therapeutic potential of Rhodiola rosea, a plant from the Crassulaceae family, has attracted increased attention. Rhodiola species are well known in traditional Chinese medicine for their ability to adapt to extreme environmental conditions, and their dried roots and rhizomes have long been used in formulations for fatigue- and hypoxia-related disorders [11, 12]. TCM invigorates Qi, promotes blood circulation, alleviates chest pain, and enhances lung function. It is commonly used for treating conditions such as Qi deficiency, blood stasis, stroke sequelae, and fatigue-related respiratory conditions and is widely incorporated in pharmaceuticals, functional foods, and dietary supplements [13–15]. Modern pharmacological studies have shown that Rhodiola and its active ingredient salidroside, SAL, exert multiple biological effects, including antioxidant, antifatigue, and antihypoxic activities, and may also ameliorate pulmonary hypertension [16]. Moreover, SAL has been shown to protect neuronal cells, regulate immune function, lower blood lipid levels, prevent arrhythmias, improve cardiac function, reduce blood glucose levels, and exert antitumor effects. Previous studies have demonstrated that SAL effectively ameliorates myocardial infarction in mice by downregulating TNF-α, TGF-β1, IL-1β, and Bax expression and upregulating Bcl2, VEGF, Akt, and eNOS expression [17]. In a mouse model of diabetic cardiomyopathy, SAL mitigated cardiac fibrosis and dysfunction, potentially through the activation of the Akt signaling pathway and the upregulation of HO-1 expression, highlighting its potential to counteract fibrosis through regulating apoptosis in myocardial tissues [17]. These findings underscore the potential of SAL as a therapeutic agent for cardiovascular diseases; however, its mechanisms in protecting against cardiac injury under high-altitude hypoxic conditions remain poorly understood. Network pharmacology, which is based on systems biology principles, integrates bioinformatics, computational science, and multitarget drug design. This approach emphasizes a holistic and systematic analysis of the complex interactions between drugs and biological systems. Chinese herbal compounds, known for their multitarget and multilevel mechanisms of action, align well with the integrative and comprehensive nature of network pharmacology, making them ideal tools for studying the pharmacological mechanisms of TCM [18, 19]. Network pharmacology has transitioned from the traditional “single-target, single-drug” paradigm to the “network-target, multicomponent” model, providing a novel, systematic approach to uncovering the therapeutic potential of traditional medicines [18]. Although traditional medicine has laid the foundation for the development of modern pharmacology, its integration with modern medicine requires rigorous research, including discovery, isolation, and mechanistic studies. Thus, basic research remains critical for advancing the application of traditional medicines in contemporary clinical practice. In this study, we utilized network pharmacology to explore the therapeutic potential of SAL in high-altitude hypoxic myocardial injury and to identify its potential molecular targets and signaling pathways. Furthermore, we conducted in vitro and in vivo experiments to further elucidate the therapeutic efficacy and underlying mechanisms of SAL in the treatment of high-altitude hypoxic myocardial injury, with a particular focus on oxidative stress and the Akt signaling pathway. This approach not only enhances our understanding of the molecular basis of the cardioprotective effects of SAL but also provides insights into its potential clinical application in high-altitude environments. Experimental Section Acquisition of SAL and Identification of Target Genes for High-Altitude Hypoxic Myocardial Injury SAL (CAS: 10338-51-9) was retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov), and its 3D structure was extracted in SDF format. The obtained structure was then uploaded into the Swiss Target Prediction database (http://www.swisstargetprediction.ch/) and PharmMapper (https://lilab-ecust.cn/pharmmapper/), with the species filter set to Homo sapiens for target prediction. To identify the molecular targets associated with high-altitude hypoxic myocardial injury, the keyword “high-altitude myocardial injury” was searched in the GeneCards (https://www.genecards.org/) and OMIM (https://www.omim.org/) databases. Redundant entries were removed to compile a list of disease-specific targets. The intersection of the SAL targets and the high-altitude hypoxic myocardial injury targets was subsequently generated via a Venn diagram, and this overlap was visualized via a bioinformatics platform (https://www.bioinformatics.com.cn). Construction of the Protein‒Protein Interaction (PPI) Network The intersecting target genes were imported into the STRING database (https://www.string-db.org/) to construct a protein–protein interaction (PPI) network, with H. sapiens selected as the organism of interest. The PPI network was subsequently visualized and analyzed using Cytoscape 3.9.1. Topological analysis was performed with the CytoNCA plugin, and degree centrality was used to assess the relative importance of each node. Genes with higher degree values were considered core targets and selected for further analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Enrichment Analyses GO analysis was performed via the DAVID Bioinformatics Resources (https://davidbioinformatics.nih.gov/) to investigate the biological processes (BP), molecular functions (MF), and cellular components (CC) associated with the identified target genes. The results were filtered for significant terms with a p value threshold of < 0.05. The top 10 enriched terms in each category were visualized via bubble plots. Additionally, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was conducted to identify the primary signaling pathways involved in the potential therapeutic effects of SAL on high-altitude hypoxic myocardial injury. Pathways with p values < 0.05 were considered significantly enriched, and the top 10 pathways are presented in bubble plots. Both the GO and KEGG analyses were performed via a bioinformatics platform, which is a comprehensive tool for data analysis and visualization. H9C2 Cell Culture The H9C2 cell line, derived from rat embryonic heart tissue (ATCC, USA), was maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Servicebio, China) supplemented with 10% fetal bovine serum (FBS) (Servicebio, China). The culture was incubated at 37 °C in a humidified 5% CO2 atmosphere. To promote optimal cell growth and proliferation, the medium was supplemented with 1% GlutaMAX (a glutamine substitute) and 1% penicillin/streptomycin (P/S). MTT Assay for Cell Viability Cell viability was assessed using an MTT assay kit, Aladdin Biochemical Technology Co., Ltd., China. H9C2 cells were seeded in 96 well plates at a density of 5 × 10⁴ cells per well and incubated overnight to allow attachment. To determine the appropriate concentration of CoCl₂ for hypoxia mimetic injury modeling, cells were treated with CoCl₂ at 0, 8, 16, 32, 64, 128, 256, and 512 µg/mL for 24 h, followed by MTT assay. To evaluate the therapeutic effect of SAL after CoCl₂ induced injury, H9C2 cells were first exposed to 128 µg/mL CoCl₂ for 24 h. After CoCl₂ treatment, the culture medium was removed and replaced with fresh medium containing SAL at 0.5, 1, 2, 4, 8, 16, 32, or 64 µg/mL, and the cells were further incubated for 24 h. After the indicated treatments, MTT solution, 5 mg/mL, was added to each well and incubated at 37 °C for 4 h. The absorbance at 570 nm was measured using a microplate reader, Thermo Fisher Scientific, USA, and cell viability was expressed as a percentage of the control group. Hoechst Staining for Apoptosis Detection Apoptotic cell death was analyzed via Hoechst 33258 staining (Beyotime Biotech, China). In brief, sterile cover slips were added to the cell culture dishes, and the cells were allowed to incubate overnight. Once the cells reached 80% confluence, they were fixed with 4% paraformaldehyde for 15 min. After fixation, the cells were stained with Hoechst 33258 (final concentration: 10 µg/mL) for 5 min. Following staining, the cells were washed three times with PBS and mounted onto glass slides for fluorescence microscopy (Leica, Germany). Apoptotic cells exhibited condensed and fragmented chromatin with intense blue staining, indicating nuclear fragmentation. Annexin V-FITC Detection of Apoptosis Annexin V-FITC/PI staining was used to detect apoptotic cells (Beyotime Biotech, China). The cells were harvested via trypsinization, washed with PBS, and resuspended. The cells were then incubated with Annexin V-FITC and PI for 10–20 min at room temperature (20–25 °C) in the dark. Apoptotic cells were quantified via flow cytometry (Layer BioTech, China) on the basis of Annexin V-FITC positivity and PI exclusion. Intracellular ROS Measurement via DCFH-DA Intracellular ROS levels were assessed via the use of a DCFH-DA fluorescent probe (Beyotime Biotech, China). DCFH-DA is de-esterified within cells to release DCFH, which, upon oxidation by ROS, becomes highly fluorescent. After H9C2 cells were exposed to 128 µg/mL CoCl2 for 24 h, they were treated with various concentrations of SAL (0, 16, 32, and 64 µg/mL) for an additional 24 h. The cells were incubated with DCFH-DA (final concentration: 10 µM) for 30 min in the dark. Following incubation, the excess probe was removed by washing with PBS, and the ROS levels were quantified via fluorescence microscopy and flow cytometry to assess the intensity of DCF fluorescence. Measurement of Mitochondrial Membrane Potential (MMP) The MMP was assessed via a JC-1 Mitochondrial Membrane Potential Detection Kit (Beyotime Biotech, China). The JC-1 staining working solution was prepared according to the manufacturer’s instructions. For the staining procedure, the cell culture medium was removed, and the cells were washed once with PBS. Afterward, 1 mL of fresh culture medium was added, followed by the addition of 500 µL of JC-1 staining working solution. The mixture was thoroughly mixed and incubated at 37 °C for 20 min. After incubation, the staining solution was aspirated, and the cells were washed twice with 1× JC-1 staining buffer. Finally, 2 mL of culture medium was added, and the cells were examined under a fluorescence microscope. JC-1 aggregates (red fluorescence) and monomers (green fluorescence) were observed to assess the MMP status. Measurement of Intracellular ATP Levels Intracellular ATP levels were measured to evaluate mitochondrial function and cell viability (Beyotime Biotech, China). A reduction in ATP levels is commonly associated with mitochondrial dysfunction and apoptosis. The cells were lysed with 200 µL of lysis buffer, and the lysates were subsequently centrifuged at 12,000 × g for 5 min at 4 °C. The supernatants were collected for ATP measurement. ATP standards were prepared and diluted in ATP detection buffer, and 100 µL of ATP detection reagent was added to each well. After a 5-minute incubation to eliminate background ATP, 20 µL of sample or standard was added to the wells, mixed, and analyzed via a luminometer. The ATP concentrations in the samples were calculated via a standard curve generated from known ATP concentrations. Assessment of Myocardial Cell Proliferation Cell proliferation was assessed via an EdU-555 cell proliferation assay kit (Beyotime Biotech, China). H9C2 cells were resuspended in complete culture medium to a final concentration of 1 × 105 cells/mL and seeded onto confocal culture plates (1 mL per well). After 24 h of incubation, the cells were treated with the corresponding intervention. EdU labeling was performed according to the manufacturer’s protocol. Following labeling, the cells were fixed, permeabilized, and washed via standard procedures. The click reaction mixture was subsequently prepared and applied to the cells, followed by incubation in the dark at room temperature for 30 min. After the reaction mixture was removed, Hoechst 33342 solution was added, and the cells were incubated in the dark at room temperature for an additional 10 min. Fluorescence images were captured via a confocal microscope. Azide 555 was visualized as red fluorescence, while Hoechst 33342 emitted blue fluorescence. EdU-positive cells and total cell counts were quantified via ImageJ software. Molecular Docking Molecular docking studies were conducted via AutoDock Vina 1.1.2 to investigate the binding mode of SAL (PubChem: 159278) with AKT1 (PDB ID: 3OS5), HIF1A (PDB ID: 4H6J), HSP90AA1 (PDB ID: 5NJX), BCL2 (PDB ID: 7LH7), FN1 (PDB ID: 1J8K), MMP9 (PDB ID: 6ESM), and ESR1 (PDB ID: 1X7R) [13]. The three-dimensional structure of AKT1 was obtained from the Protein Data Bank (RCSB PDB, www.rcsb.org), while the 3D structure of SAL was meticulously constructed via ChemBioDraw Ultra 14.0 software. The docking input files were generated via AutoDockTools 1.5.6. Prior to docking, the ligand structure was optimized by merging nonpolar hydrogen atoms and defining rotatable bonds. The search grid for AKT1 was centered at coordinates (center_x: 21.578; center_y: 14.614; center_z: 9.955), with a grid size of (size_x: 45.0; size_y: 47.25; size_z: 47.25), ensuring the precision and reliability of the docking process. Molecular Electrostatic Potential (MEP) Analysis of SAL Molecular electrostatic potential, MESP, analysis was performed to characterize the surface electron distribution of SAL. The geometric structure of SAL was first fully optimized by density functional theory, DFT, using the B3LYP functional with the 6-31G* basis set. All quantum chemical calculations, including geometry optimization and electronic structure analysis, were carried out using the Gaussian 09 computational package. Based on the optimized structure, the molecular electrostatic potential of SAL was calculated, and the corresponding MESP map was generated from the cube files exported by Gaussian. This analysis was used to visualize the charge distribution on the molecular surface of SAL and to identify regions with distinct electrostatic characteristics. Reverse Transcription‒Quantitative PCR (RT‒qPCR) Total RNA from H9C2 cells and rat cardiac tissue was extracted via TRIzol reagent, and complementary DNA (cDNA) was synthesized via a reverse transcription kit. RT‒qPCR was performed with the specific primers listed in Table 1, and all reagents were obtained from Servicebio, China. Gapdh was used as an internal control for normalization. Gene expression levels were evaluated via the 2⁻ΔΔCt method, and all the assays were conducted in triplicate to ensure reproducibility. Table 1Primers used in RT‒qPCRPrimersNucleotide sequence (5’→ 3’) gapdh ForwardGGCAAGTTCAACGGCACAGTReverseGCCAGTAGACTCCACGACAT sod2 ForwardATTGCCGCCTGCTCTAATCReverseGATAGTAAGCGTGCTCCCACA cat ForwardTTGCCAACCACCTGAAAGATReverseAGGGTGGACGTCAGTGAAAT bax ForwardAACTTCAACTGGGGCCGCGTGGTTReverseCATCTTCTTCCAGATGGTGAGCGAG bcl2 ForwardGCAGCTTCTTTCCCCGGAAGGAReverseAGGTGCAGCTGACTGGACATCT akt ForwardAGACCGACACCAGGTATTTReverseAGTAGGAGAACTGGGGAAA gsk-3β ForwardTGGACAGACCAATAACGCCGReverseGTGACCAGTGTTGCTGAGTG Primers used in RT‒qPCR Western Blot Analysis Total protein from H9C2 cells and rat cardiac tissue was extracted using RIPA lysis buffer supplemented with phosphatase inhibitors, and the protein concentration was determined using a BCA protein assay kit (Servicebio, China). Equal amounts of protein (35 µg per lane) were separated by 12% SDS‒PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% skim milk in TBST for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against p-Akt Ser473 (GB150002-50; Servicebio, Wuhan, China), Akt (GB15689-50; Servicebio, Wuhan, China), p-GSK-3β Ser9 (GB114582-50; Servicebio, Wuhan, China), GSK-3β (GB111694-50; Servicebio, Wuhan, China), cTnI (GB112408-50; Servicebio, Shanghai, China), SOD2 (GB111875-50; Servicebio, Wuhan, China), CAT (AG1341; Beyotime, Shanghai, China), Bax (GB15690-50; Servicebio, Wuhan, China), Bcl2 (GB154380-50; Servicebio, Wuhan, China), cleaved caspase-7 (GB115728-50; Servicebio, Wuhan, China), cleaved caspase-3 (GB11532-50; Servicebio, Wuhan, China), and GAPDH (GB15004-100; Servicebio, Wuhan, China). All primary antibodies were used at a dilution of 1:2000. After being washed, the membranes were incubated with HRP-conjugated goat anti-rabbit IgG or goat anti-rat IgG secondary antibodies (GB23302, GB23303; Servicebio, Wuhan, China) at a dilution of 1:5000 for 2 h at room temperature. The protein bands were visualized using an enhanced chemiluminescence kit and quantified relative to those of GAPDH. Pharmacological Inhibition of Akt Signaling To further evaluate the involvement of Akt signaling in the protective effect of SAL, H9C2 cells were subjected to pharmacological inhibition using the selective Akt inhibitor MK-2206. Cells were assigned to the following groups: Control, CoCl2, CoCl2 + SAL, MK-2206 (10 µM), CoCl2 + MK-2206 (10 µM), and CoCl2 + SAL + MK-2206 (10 µM). CoCl2 was first applied to induce hypoxia-mimetic injury, after which SAL and/or MK-2206 were added according to the experimental design. Total protein was extracted after treatment, and the expression levels of p-Akt Ser473, total Akt, p-GSK-3β Ser9, total GSK-3β, Bax, and Bcl2 were analyzed by Western blotting. CoCl2-Induced Chemical Hypoxia Model in Rats and SAL Treatment Evaluation Adult male Sprague–Dawley (SD) rats (200 ± 20 g, 8 weeks old) were obtained from Liaoning Changsheng Biotechnology Co., Ltd. All the animal procedures were conducted in accordance with the Guidelines for Animal Experiments of the Medical Ethics Committee and approved by the Institutional Animal Care and Use Committee of Jilin University School of Pharmaceutical Science. A total of 20 rats were randomly divided into five groups (n = 4 per group): [20] the control group, which received an equal volume of PBS intraperitoneally for 7 days; [21] the CoCl2 group, which was treated with CoCl2 (30 mg/kg/day, i.p.) for 7 days; [22] the low-dose SAL group, which was administered SAL at 20 mg/kg/day (i.p.) for 7 days; [9] the medium-dose SAL group, which was treated with 40 mg/kg/day SAL; and [23] the high-dose SAL group, which was treated with 80 mg/kg/day SAL. In the treatment groups, SAL was administered concurrently with CoCl2 exposure, as previously described (Belaidi et al., 2012). On day 8, electrocardiograms (ECGs) were recorded, and blood samples were collected. The rats were anesthetized with sodium pentobarbital (50 mg/kg, intravenous injection), and the heart, liver, and lungs were rapidly excised. The wet weight of the left lung was measured via a precision electronic balance. The lung tissues were then dried at 55 °C for 72 h to obtain a constant dry weight, and the lung water content was calculated as follows: (wet weight − dry weight)/wet weight × 100% (Pan et al., 2020). Surface Electrocardiogram (ECG) Recording Electrocardiographic measurements were performed via a BL420 biological signal acquisition and processing system (Taimeng, Sichuan, China). After anesthesia with sodium pentobarbital (50 mg/kg, i.v.), the rats were placed in the supine position on a fixation board. Needle electrodes were inserted subcutaneously into the limbs: a red electrode was inserted into the right forelimb, a black electrode was inserted into the right hindlimb, and a green electrode was inserted into the left hindlimb. Lead II was used for recording, with a gain of 1 mV = 10 mm and a paper speed of 50 mm/s (Zhou et al., 2015). Histopathological Analysis Excised heart, lung, and liver tissues were fixed in 4% paraformaldehyde, dehydrated, embedded in paraffin, and sectioned at a thickness of 5 μm. For H&E staining, tissue sections were deparaffinized in xylene, rehydrated through a graded ethanol series, stained with hematoxylin, differentiated, counterstained with eosin, dehydrated, cleared, and mounted for microscopic observation. For WGA staining, paraffin sections were deparaffinized, rehydrated, permeabilized, blocked, and incubated with WGA staining solution according to the manufacturer’s protocol, followed by nuclear counterstaining with DAPI and mounting. Histological images were captured using an Olympus Olyvia light microscope. The cardiomyocyte cross-sectional area was quantified using ImageJ software. Serum Biochemical Analysis Serum samples were collected from the rats in each group to evaluate hepatic injury. Serum ALT and AST activities were measured using the Amplex Red ALT Activity Assay Kit and Amplex Red AST Activity Assay Kit (Beyotime, Shanghai, China) according to the manufacturer’s instructions. Briefly, serum samples were mixed with the reaction working solution and incubated under protected light conditions, after which the fluorescence intensity was measured using a microplate reader. ALT and AST activities were calculated on the basis of standard curves generated in parallel. Statistical Analysis All experiments were independently repeated at least three times unless otherwise stated. The data are presented as the mean ± SD. Comparisons among multiple groups were performed using one-way ANOVA followed by Tukey’s multiple comparisons test. For datasets involving two independent variables, two-way ANOVA followed by Bonferroni post hoc correction was used where appropriate. Statistical analyses were performed using GraphPad Prism 9.0 (GraphPad Software, San Diego, CA, USA). A value of P < 0.05 was considered to indicate statistical significance. Results Network Pharmacology Analysis of SAL-Associated Targets in Hypoxia-Mimetic Myocardial Injury In this study, the two-dimensional structure and CAS number of the SAL were retrieved from the PubChem database and subsequently imported into the Swiss Target Prediction and PharmMapper databases to identify 166 unique targets. Additionally, 643 high-altitude myocardial injury-associated target genes were identified from the GeneCards and OMIM databases. A Venn diagram was constructed to visualize the overlap between the targets of SAL and those related to high-altitude myocardial injury, revealing 34 common targets as potential mediators of the therapeutic effects of SAL (Fig. 1A). These 34 overlapping targets were further imported into the STRING database to construct a protein–protein interaction (PPI) network (Fig. 1B). Using Cytoscape 3.9.1 software, a drug‒target relationship network was constructed, and the connectivity of the target nodes was calculated, resulting in 31 nodes and 179 edges (Fig. 1C). On the basis of topological analysis using the CytoNCA plugin, the top seven targets with the highest degree values were identified: protein kinase B (AKT1, degree = 23.0), hypoxia-inducible factor 1-alpha (HIF1A, degree = 21.0), heat shock protein 90 alpha family A member 1 (HSP90AA1, degree = 20.0), B-cell lymphoma-2 apoptosis regulator (BCL2, degree = 20.0), fibronectin 1 (FN1, degree = 19.0), matrix metalloproteinase 9 (MMP9, degree = 19.0), and estrogen receptor 1 (ESR1, degree = 19.0), which are considered key therapeutic targets of SAL in the treatment of high-altitude myocardial injury (Fig. 1D). Furthermore, GO and KEGG enrichment analyses were conducted on the 34 common target genes via the DAVID platform. A total of 197 BP terms associated with the therapeutic effects of SAL on high-altitude myocardial injury, which primarily involve responses to specific stresses, negative regulation of the apoptotic process, and positive regulation of transcription from DNA templates, were identified. Among these genes, AKT1, HIF1A, BCL2, and FN1 are closely related to apoptosis, whereas AKT1 and HIF1A are involved in specific stress responses. Additionally, 21 CCs, including the myelin sheath, protein-containing complex, cell surface, and cytosol, were identified. AKT1 and HIF1A are located predominantly in the cytoplasm; BCL2 is located in the nuclear membrane, endoplasmic reticulum membrane, and outer mitochondrial membrane; and FN1 and MMP9 are found in the extracellular fluid. A total of 34 MFs were enriched, including those involved in sequence-specific DNA binding, ubiquitin-protein ligase binding, and estrogen response element binding (Fig. 1E). KEGG enrichment analysis revealed that the therapeutic effects of SAL on high-altitude myocardial injury include longevity regulation, chemical carcinogenesis-receptor activation, diabetic cardiomyopathy, and HIF-1α signaling (Fig. 1F). Overall, this integrative approach not only provides novel insights into the molecular mechanisms underlying the therapeutic potential of SAL but also lays the groundwork for future research aimed at exploiting these pathways for the treatment of high-altitude myocardial injury. Network pharmacology analysis of the potential targets of Sal in the treatment of high-altitude myocardial injury. A Venn diagram illustrating the overlap between potential targets of SAL and those associated with high-elevation hypoxic myocardial injury (HACI). B PPI network showing the molecular interactions of the identified targets. C Drug‒target interaction network representing the connections between SAL and its targets. D Key targets involved in the therapeutic effect of SAL on hypoxic myocardial injury. E, F GO enrichment analysis (E) and KEGG pathway analysis (F) of the genes intersecting between SAL and hypoxic myocardial injury Network Pharmacology and Molecular Docking Prioritize AKT1 as a Candidate Target of SAL In this study, molecular electrostatic potential (MESP) calculations were employed to investigate the noncovalent interactions between SAL and it s target proteins. In the electrostatic potential map, the blue regions indicate electron-deficient areas, the red regions represent electron-rich areas, and the green regions denote neutral zones. The red regions indicate electron-rich areas with relatively negative electrostatic potential, whereas the blue regions indicate electron-deficient areas with relatively positive electrostatic potential (Fig. 2A). This electrostatic interaction may influence the binding mode and strength of the interaction of SAL with AKT1, thereby affecting its biological activity. Molecular docking evaluation of the top seven target genes screened by network pharmacology with SAL. A Electrostatic potential map of the SAL. B–H Molecular docking simulations demonstrating the binding interactions between SAL and the following predicted target proteins: AKT1 (B), HIF1A (C), HSP90AA1 (D), BCL2 (E), FN1 (F), MMP9 (G), and ESR1 (H) Molecular docking experiments were subsequently conducted via AutoDock Tools 1.5.6 to assess the binding efficiency between SAL and the top seven target genes identified through network pharmacology. The results indicated that SAL strongly binds to the active sites of AKT1, HIF1A, HSP90AA1, BCL2, FN1, MMP9, and ESR1 (Fig. 2B‒H). Notably, noncovalent interactions, including hydrogen bonds, carbon‒hydrogen bonds, π‒π stacking interactions, and hydrophobic forces, were observed between the functional groups of SAL and key amino acid residues in these target proteins. Among these interactions, the AKT1-SAL complex exhibited a relatively high binding energy of -6.2 kcal/mol, with more hydrogen bonds formed than the other target complexes did. This suggests that the most robust interaction occurs through hydrogen bonds at the LYS-8, TRP-11, GLU-91, GLU-98, and TRP-99 residues of AKT1 (Fig. 2B). These specific interactions are likely to play pivotal roles in the stability and potency of SAL-AKT1 binding. Furthermore, AKT1 is a critical regulator of cellular processes such as proliferation, differentiation, and apoptosis and is closely associated with the pathogenesis of diabetic cardiomyopathy. In this context, activation of the AKT1 pathway offers multiple cardioprotective benefits, including improved glucose metabolism, enhanced insulin sensitivity, regulation of disturbed energy metabolism, and attenuation of chronic inflammation [20]. These findings underscore the potential role of SAL in modulating cellular processes, including apoptosis, oxidative stress, and inflammation, which are essential for its protective effects against high-altitude hypoxic myocardial injury. In conclusion, the combination of network pharmacology and molecular docking analysis identified AKT1 as a key target of SAL. The docking results revealed strong binding interactions, suggesting that the therapeutic effects of SAL on high-altitude hypoxic myocardial injury may occur through the modulation of AKT1. These findings provide a molecular basis for further exploration of SAL as a potential therapeutic agent. Inhibitory Effect of SAL on CoCl2-Induced Cytotoxicity in H9C2 Cells In this study, CoCl2 (a chemical hypoxia inducer that stabilizes HIF-1α, thereby mimicking hypoxic conditions) was used to establish a model of high-altitude hypoxic cardiac injury. The aim of this study was to investigate the protective effects of SAL on CoCl2-induced cytotoxicity in H9C2 cells, thereby elucidating its potential role in protecting myocardial cells from high-altitude hypoxia-induced damage. The chemical structure of SAL is shown in Fig. 3A. A quality test of SAL by high-performance liquid chromatography (HPLC) is shown in Supplementary Fig. 1. Protective effects of SAL on CoCl2-induced H9C2 cell injury. A Chemical structure of SAL. B Viability of H9C2 cells treated with different concentrations of CoCl2 (0, 8, 16, 32, 64, 128, 256, and 512 µg/mL) for 24 h, as assessed by the MTT assay. C Viability of H9C2 cells treated with increasing concentrations of SAL (0 - 256 µg/mL) for 24 h, as measured by the MTT assay. D H9C2 cells were first exposed to 128 µg/mL CoCl2 for 24 h to establish hypoxia-mimetic injury and were then treated with the indicated concentrations of SAL for an additional 24 h. E Cell proliferation was assessed via EdU labeling (red), and the cell nuclei were counterstained with Hoechst 33342 (blue). The results show the proliferative activity of H9C2 cells under different SAL treatments following CoCl2 exposure. F EdU-positive cells (red fluorescence) were quantitatively assessed using ImageJ software. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (128 μg/mL CoCl2 and 0 μg/mL SAL) To determine the toxic effects of CoCl2 on H9C2 cells, H9C2 cells were treated with different concentrations of CoCl2 (0–512 µg/mL) for 24 h. MTT assays revealed a significant reduction in cell viability at all the tested concentrations of CoCl2 (P < 0.001; Fig. 3B), indicating that CoCl2 effectively induced cytotoxicity and simulated hypoxic damage. Next, we evaluated the toxicity of various concentrations of SAL (0–256 µg/mL) on H9C2 cells. MTT assays revealed that concentrations ranging from 0 to 64 µg/mL did not significantly affect cell viability, whereas concentrations ranging from 128 to 256 µg/mL significantly reduced cell viability (P < 0.05; Fig. 3C), suggesting that high concentrations of SAL may have certain toxic effects on cells. Therefore, lower doses of SAL were selected to further investigate its protective effects. To explore the effect of SAL on CoCl2-induced cytotoxicity in greater detail, H9C2 cells were first treated with 128 µg/mL CoCl2 for 24 h and then treated with 16, 32, or 64 µg/mL SAL for 24 h. MTT assays revealed that treatment with 32 and 64 µg/mL SAL significantly inhibited the CoCl2-induced decrease in cell viability, increasing cell viability to 79.61 ± 4.81% and 84.02 ± 3.17%, respectively (P < 0.001; Fig. 3D). These results suggest that within a specific concentration range, SAL effectively mitigates CoCl2-induced cytotoxicity and exerts a protective effect on cells. EdU (5-ethynyl-2’-deoxyuridine) is a novel thymidine analog that is specifically incorporated into DNA during the S phase of the cell cycle and serves as a reliable marker of cellular proliferation. In this study, the number of EdU-positive H9C2 cells (red fluorescence) was significantly lower in the CoCl2-treated group than in the untreated control group (Fig. 3E–F), indicating that CoCl2-induced chemical hypoxia markedly suppressed cell proliferation. However, treatment with SAL led to a dose-dependent increase in the proportion of EdU-positive cells relative to that in the model group. Notably, compared with the CoCl2 group, the 64 µg/mL SAL-treated group presented a significantly greater number of EdU-positive cells, suggesting that SAL promotes cell proliferation in a dose-dependent manner and partially restores proliferative capacity under hypoxic conditions, thereby providing cytoprotective effects against CoCl2-induced hypoxic injury in cardiomyocytes. Inhibitory Effect of SAL on CoCl2-Induced H9C2 Cell Apoptosis The inhibitory effect of SAL on CoCl2-induced H9C2 cell apoptosis was assessed via Hoechst 33342 staining. In the CoCl2-only treatment group, the nuclei exhibited intense, fragmented staining and significantly enhanced fluorescence, indicating a marked increase in the degree of apoptosis (Fig. 4A). After treatment with different concentrations of SAL (16, 32, and 64 µg/mL), the rate of apoptosis induced by CoCl2 was significantly reduced. Specifically, 32 and 64 µg/mL SAL reduced the percentage of apoptotic cells to 67.72 ± 5.13% and 34.22 ± 5.09%, respectively (P < 0.05; Fig. 4C). Protective effects of salidroside on CoCl2-induced H9C2 apoptosis. A H9C2 apoptosis following CoCl2-induced damage and different SAL treatments was assessed via Hoechst staining. B Flow cytometry analysis of H9C2 apoptosis after exposure to CoCl2 and treatment with different concentrations of SAL. C Quantification of apoptotic nuclei identified by Hoechst staining under fluorescence microscopy. D Quantification of apoptotic H9C2 cells based on Annexin V-FITC/PI flow cytometry analysis. Total apoptosis was defined as the sum of early apoptotic, Annexin V-positive and PI-negative, cells and late apoptotic, Annexin V-positive and PI-positive, cells. E Regulation of apoptosis-related proteins, including cleaved caspase-3 and cleaved caspase-7, by SAL in CoCl2-treated H9C2 cells. F Modulation of the expression of the cardiac injury marker cTnI in H9C2 cells by CoCl2. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (128 µg/mL CoCl2 and 0 µg/mL SAL) Flow cytometry analysis further confirmed that CoCl2 treatment of H9C2 cells for 24 h significantly increased the percentage of apoptotic H9C2 cells, demonstrating the effective induction of apoptosis by CoCl2. After treatment with SAL, the rate of apoptosis induced by CoCl2 was partially reduced (Fig. 4B&D), indicating that SAL has significant antiapoptotic effects and effectively suppresses CoCl2-induced apoptosis. Compared with those in the control group, the expression levels of cleaved caspase-3 (cleaved at Asp175) and cleaved caspase-7 (cleaved at Asp198) were significantly greater in the CoCl2-treated group. Treatment with SAL reversed the expression levels of these apoptosis-related proteins to near normal levels (P < 0.001; Fig. 4E), suggesting that SAL may exert its antiapoptotic effect by modulating the expression of apoptosis-related proteins. Furthermore, the relative protein expression levels of the cardiac injury marker cardiac troponin I (cTnI) significantly increased after CoCl2 treatment, whereas SAL treatment significantly reduced the expression of cTnI in a dose-dependent manner (P < 0.05; Fig. 4F), further confirming that SAL protects H9C2 cells from CoCl2-induced apoptosis and cellular damage. Inhibitory Effect of SAL on CoCl2-Induced Damage to Mitochondrial Oxidative Stress in H9C2 Cells The effect of SAL on the redox status of CoCl2-treated H9C2 cells was assessed by measuring intracellular ROS levels via DCFH-DA (Fig. 5A). CoCl2 treatment resulted in strong green fluorescence, indicating a significant increase in ROS production. However, when H9C2 cells were cotreated with 32 and 64 µg/mL SAL, CoCl2-induced ROS levels were significantly reduced by approximately 60% and 90%, respectively (P < 0.001; Fig. 5B&D). Flow cytometry analysis also confirmed that CoCl2 treatment significantly increased ROS levels from 3.26% to 69.1%. SAL at 32 and 64 μg/mL reduced the proportion of ROS-positive cells from 69.1% to 45.1% and 27.0%, respectively. (Fig. 5C&E). These results indicate that SAL has significant antioxidant effects and can effectively suppress CoCl2-induced mitochondrial oxidative stress. SAL protects mitochondria from CoCl2-induced oxidative stress in H9C2 cells. A Schematic diagram of the detection of ROS accumulation in H9C2 cells following CoCl2 and SAL treatment with a DCFH-DA probe. B Detection of ROS accumulation in H9C2 cells following CoCl2 treatment and SAL treatment via the use of a DCFH-DA probe. C Flow cytometry analysis of intracellular ROS levels in H9C2 cells after CoCl2 treatment and SAL treatment. D The ROS fluorescence intensity was quantified via ImageJ software. E Quantitative analysis of intracellular ROS-positive cells based on flow cytometry. F, G SAL modulates the transcription (F) and protein expression (G) levels of CAT. H, I SAL regulates the transcription (H) and protein expression (I) levels of SOD2. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (128 µg/mL CoCl2 and 0 µg/mL SAL) Furthermore, RT‒qPCR and Western blot analyses revealed that compared with the control treatment, CoCl2 treatment significantly decreased the transcription and protein expression levels of mitochondrial antioxidant enzymes, including superoxide dismutase 2 (SOD2) and catalase (CAT) (P < 0.001; Fig. 5F‒I). CoCl2-induced hypoxia is known to impair mitochondrial antioxidant defenses, leading to oxidative stress. Treatment with SAL restored the expression of these enzymes to levels similar to those of the control group (P < 0.001; Fig. 5F‒I), suggesting that SAL may exert its protective effects by modulating the expression of proteins involved in mitochondrial oxidative stress. SAL Improved Mitochondrial Dysfunction in CoCl2-Treated H9C2 Cells Mitochondrial membrane potential was assessed using the JC-1 probe. As shown in Fig. 6A, C, control cells predominantly exhibited red JC-1 aggregate fluorescence, whereas CoCl2-treated cells showed a marked increase in green JC-1 monomer fluorescence, indicating dissipation of mitochondrial membrane potential. SAL treatment attenuated this shift, particularly at 32 and 64 µg/mL, suggesting partial restoration of mitochondrial integrity (Fig. 6A, C). Consistent with the JC-1 results, CoCl2 significantly reduced intracellular ATP levels, whereas SAL treatment increased ATP production compared with that in the CoCl2 group, with the most evident recovery observed at 64 µg/mL (Fig. 6B). In addition, RT–qPCR analysis showed that CoCl2 increased bax mRNA expression and decreased bcl2 mRNA expression, whereas SAL treatment partially reversed these changes (Fig. 6D, E). Western blot analysis further confirmed that CoCl2 elevated Bax protein expression and reduced Bcl2 protein expression, whereas SAL treatment restored the Bcl2/Bax balance toward the control pattern (Fig. 6F). Together, these results indicate that SAL alleviated CoCl2-induced mitochondrial dysfunction and apoptosis-related mitochondrial injury in H9C2 cells. SAL improved mitochondrial function and partially restored Akt/GSK-3β signaling balance in CoCl2-treated H9C2 cells. A Representative JC-1 staining images showing mitochondrial membrane potential in H9C2 cells after CoCl2 exposure and SAL treatment. Red fluorescence indicates JC-1 aggregates, whereas green fluorescence indicates JC-1 monomers. Scale bar, 200 μm. B Intracellular ATP levels in H9C2 cells after CoCl2 exposure and SAL treatment. C Quantitative analysis of mitochondrial membrane potential based on JC-1 fluorescence. D Relative bax mRNA expression in H9C2 cells after CoCl2 exposure and SAL treatment. E Relative bcl2 mRNA expression in H9C2 cells after CoCl2 exposure and SAL treatment. F Representative Western blots and densitometric quantification of Bax and Bcl2 in H9C2 cells after CoCl2 exposure and SAL treatment. G Relative akt mRNA expression in H9C2 cells after CoCl2 exposure and SAL treatment. H Representative Western blots and densitometric quantification of p-Akt Ser473 and total Akt in H9C2 cells after CoCl2 exposure and SAL treatment. I Relative gsk-3β mRNA expression in H9C2 cells after CoCl2 exposure and SAL treatment. J Representative Western blots and densitometric quantification of p-GSK-3β Ser9 and total GSK-3β in H9C2 cells after CoCl2 exposure and SAL treatment. Data are presented as mean ± SD from three independent experiments. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (128 µg/mL CoCl2 and 0 µg/mL SAL) SAL Modulates the Akt/GSK-3β Signaling Axis, but its Promotion of GSK-3β Phosphorylation and Anti-Apoptotic Effects are Largely Akt-Independent To further examine whether the Akt/GSK-3β signaling axis was altered during CoCl2-induced injury and SAL intervention, we assessed the transcriptional and phosphorylation status of Akt and GSK-3β in H9C2 cells and further evaluated the effect of Akt inhibition. RT–qPCR analysis showed that CoCl2 treatment markedly increased akt mRNA expression and decreased gsk-3β mRNA expression compared with those in the control group, whereas SAL treatment partially reversed these changes, particularly at 32 and 64 µg/mL (Fig. 6G, I). Western blot analysis revealed that CoCl2 stress significantly increased p-Akt Ser473 (likely as a compensatory stress response) and reduced p-GSK-3β Ser9. SAL treatment shifted this altered phosphorylation pattern toward a more balanced state, with the recovery of inhibitory phosphorylation of GSK-3β being notably evident (Fig. 6H, J). To definitively determine the dependency of these effects on upstream Akt signaling, cells were treated with the selective Akt inhibitor MK-2206. The inhibitor effectively abolished p-Akt levels without substantially affecting total Akt expression, confirming the successful blockade of Akt phosphorylation. Strikingly, under conditions of profound Akt inhibition, the ability of SAL to promote GSK-3β phosphorylation at Ser9 was not attenuated; rather, p-GSK-3β levels remained robustly elevated (Supplementary Fig. 3). Furthermore, the regulatory effects of SAL on apoptosis-related proteins were largely maintained, as SAL still effectively restored Bcl2 expression and reduced Bax expression in the presence of MK-2206. These findings indicate that while SAL normalizes the altered Akt/GSK-3β signaling balance under hypoxic stress, its potent promotion of GSK-3β inhibitory phosphorylation and the subsequent anti-apoptotic protection in CoCl2-treated H9C2 cells are largely mediated through an Akt-independent mechanism. Effects of SAL on Electrocardiographic and Histopathological Changes in a CoCl2-Induced Hypoxic Myocardial Injury Model in Rats A hypoxic myocardial injury model was established in rats via intraperitoneal injection of CoCl2. Subcutaneous needle electrodes were inserted between the paw pads of each rat, and ECG signals were continuously recorded (Fig. 7A). Compared with the control group, the CoCl2-induced group presented significant electrocardiographic abnormalities, including prolonged ST intervals, ST segment elevation, and reduced R-wave amplitude, which are indicators of myocardial ischemia, injury, or necrosis (Fig. 7B). SAL treatment markedly ameliorated these ECG abnormalities, as evidenced by the return of the ST segment to baseline and partial recovery of the R-wave amplitude (Fig. 7B), suggesting that SAL effectively mitigated CoCl2-induced cardiac dysfunction. To further elucidate the mechanisms underlying this protective effect, RT‒qPCR and Western blot analyses were performed. In myocardial tissues from the CoCl2-treated group, both the transcription and protein expression levels of the mitochondrial antioxidant enzymes SOD2 and CAT significantly decreased. SAL treatment restored the expression of these oxidative stress-related proteins to levels comparable to those in the control group (P < 0.001; Fig. 7C–F), indicating that SAL may exert cardioprotective effects by modulating mitochondrial oxidative stress pathways. Additionally, the CoCl2-treated group presented a marked decrease in the expression of the antiapoptotic protein Bcl2 and a concomitant increase in the expression of the proapoptotic protein Bax. SAL treatment effectively restored the Bcl2/Bax ratio to near-normal levels (P < 0.001; Fig. 7G–J), further suggesting that the cardioprotective effect of SAL is mediated, at least in part, through the inhibition of apoptosis via regulation of the Bcl2/Bax signaling axis. Effect of SAL on the electrocardiogram and histopathological changes in hypoxia-induced rat hearts induced by CoCl2. A Animal experimental model of CoCl2-induced hypoxia in rat hearts and treatment with SAL. B Effect of SAL on CoCl2-induced cardiac injury as determined by electrocardiography. C, D SAL regulates the transcription levels of CAT (C) and SOD2 (D) in the cardiac tissue of rats exposed to cobalt chloride-induced hypoxia. E, F Modulation of the protein expression levels of CAT (E) and SOD2 (F) by SAL in the cardiac tissue of rats exposed to cobalt chloride-induced hypoxia. G, H SAL regulates the transcription levels of Bcl2 (G) and Bax (H) in the cardiac tissue of rats exposed to cobalt chloride-induced hypoxia. I, J Modulation of the protein expression levels of Bcl2 (I) and Bax (J) by SAL in the cardiac tissue of rats exposed to cobalt chloride-induced hypoxia. K H&E staining of rat cardiac tissue, the arrows indicate myocardial pathological changes in the CoCl₂ model group, including interstitial edema, inflammatory cell infiltration, and myocardial fiber structure disruption. In the SAL treatment group, the arrows indicate a dose-dependent significant reduction in these pathological changes. Scale bar = 100 μm. L WGA staining of rat cardiac tissue; scale bar = 20 μm. M ImageJ software was used to quantitatively assess the area of WGA-stained cardiomyocytes. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (30 mg/kg CoCl2 and 0 mg/kg SAL) Histological examination via H&E staining revealed well-preserved myocardial architecture in the control group, with orderly arranged cardiomyocytes, intact cell membranes, and clearly defined nuclei, without signs of myocyte rupture. In contrast, the CoCl2 group presented pronounced interstitial edema, inflammatory cell infiltration, and myofiber disruption. SAL-treated rats displayed notable improvements in myocardial architecture, with reduced inflammatory infiltration and myofibrillar integrity, indicating that SAL mitigated CoCl2-induced structural myocardial damage (Fig. 7K). WGA staining further revealed that CoCl2 exposure resulted in significant cardiomyocyte hypertrophy, characterized by thickened myofibers. SAL treatment led to a marked reduction in both cardiomyocyte diameter and wall thickness, further supporting its protective effect against CoCl2-induced myocardial injury (Fig. 7L–M). To investigate the underlying signaling mechanisms, the effects of SAL on GSK-3β and Akt expression in hypoxic myocardial tissue were examined. RT‒qPCR analysis demonstrated that CoCl2 stimulation significantly upregulated akt gene transcription while downregulating gsk-3β gene transcription. SAL treatment reversed these alterations, restoring the expression levels of both genes to baseline levels (P < 0.001; Supplementary Fig. 2), suggesting that the cardioprotective effects of SAL occur at least in part through modulation of the Akt/GSK-3β signaling pathway. Collectively, these findings demonstrate that SAL not only alleviates electrocardiographic abnormalities but also attenuates histopathological damage in a CoCl2-induced hypoxic myocardial injury model. These results provide compelling evidence that SAL is a potential therapeutic agent for the treatment of hypoxia-induced myocardial dysfunction. Effects of SAL on Histopathological Alterations in the Lungs and Livers of Rats Subjected to CoCl2-Induced Hypoxia. In addition to those in the heart, structural and functional changes in other vital organs, including the lungs and liver, were also evaluated across the different experimental groups (Fig. 8A). H&E staining revealed that the lung tissues from the CoCl2-induced group presented significant pathological alterations, including intra-alveolar exudates, massive infiltration of inflammatory cells, thickening of the alveolar septa, disorganized bronchial epithelial arrangement, narrowed and deformed bronchial lumens, and dense peribronchial inflammatory cell accumulation. These abnormalities were substantially attenuated in the rats treated with SAL. Notably, in the groups treated with 40 and 80 mg/kg SAL, the amount of alveolar exudates was markedly reduced, the alveolar walls appeared thinner, and the overall lung architecture approached normal. Furthermore, the number of infiltrating inflammatory cells decreased to approximately 60% and 50% of that in the CoCl2 model group, respectively (Fig. 8B–C). Effects of SAL on CoCl2-induced histopathological changes in the lungs and liver of rats. A Animal experimental model of CoCl2-induced hypoxia in rat lungs and liver and treatment with SAL. B H&E-stained images of lung tissue sections from each experimental group; the arrows indicate lung tissue damage in the CoCl₂ model group, characterized by alveolar exudation, inflammatory cell infiltration, alveolar septal thickening, bronchial epithelial disarray, and bronchial luminal narrowing. In the SAL treatment group, the arrows indicate a dose-dependent significant reduction in these pathological changes. Scale bar = 100 μm. C Quantitative analysis of inflammatory cell infiltration in lung tissue based on H&E staining. All the data are presented as the means ± SDs (n = 4). D Lung water content (n = 4). E, F Serum AST (E) and ALT (F) protein levels were analyzed by ELISA. All the data are presented as the means ± SDs (n = 4) (G). H&E staining images of liver tissue sections from each group; The arrows indicate hypoxia-related liver changes in the CoCl₂ model group, including disordered hepatic cords, hepatocyte edema, and irregular cell arrangement. In the SAL treatment group, the arrows indicate a significant dose-dependent reduction in these pathological changes. Scale bar = 100 μm. ns, no significant difference; *P < 0.05; **P < 0.01; ***P < 0.001, compared with the CoCl2 alone group (30 mg/kg CoCl2) To further assess pulmonary injury under hypoxic conditions, the lung water content was measured as an index of pulmonary edema. Compared with the control group, the CoCl2-induced group presented a significant increase in lung water content, indicating the development of pulmonary edema. In contrast, SAL administration significantly reduced the lung water content, demonstrating its protective role in alleviating pulmonary fluid accumulation (Fig. 8D). These findings suggest that SAL protects lung tissue from hypoxia-induced damage primarily by reducing pulmonary edema and suppressing inflammatory responses. To evaluate hepatic injury under hypoxic stress, the serum levels of AST and ALT were measured. CoCl2 exposure significantly elevated both AST and ALT levels, indicating the presence of hepatocellular injury. SAL treatment significantly reduced the levels of these serum markers of liver damage. Specifically, 40 and 80 mg/kg SAL reduced serum AST levels to 65.52 ± 1.17% and 37.12 ± 2.09%, respectively, and serum ALT levels to 52.01 ± 1.19% and 48.82 ± 1.06%, respectively (Fig. 8E–F), confirming its hepatoprotective effects. H&E staining of liver tissues further corroborated these findings. The control group presented well-preserved hepatic architecture, with intact cellular structures and clearly defined nuclei, without signs of histological damage. In contrast, CoCl2 exposure resulted in disrupted hepatic cord structures, disordered hepatocyte arrangement, and pronounced hepatic edema, despite the absence of overt necrosis. Treatment with SAL restored hepatic cord architecture, significantly reduced edema, and improved overall histological integrity (Fig. 8G). Collectively, these results demonstrate that SAL treatment significantly mitigated CoCl2-induced histopathological damage to both the lungs and liver. These findings highlight the potential of SAL as a protective agent against hypoxia-induced multiorgan injury, particularly in pulmonary and hepatic tissues. Discussion In the present study, we systematically investigated the cardioprotective efficacy and underlying mechanisms of salidroside (SAL) against hypoxia-mimetic injury. Hypoxia-induced myocardial damage remains a profound pathophysiological challenge, as cardiomyocytes rely heavily on a continuous oxygen supply to maintain mitochondrial oxidative phosphorylation and contractile function [24–26]. Under hypoxic stress, the myocardium undergoes a cascade of pathological changes, primarily characterized by oxidative stress, mitochondrial dysfunction, and apoptosis [27]. While SAL, a major bioactive constituent of Rhodiola, has demonstrated antioxidant and antiapoptotic properties across various experimental models [17, 23, 28, 29], its specific efficacy under conditions mimicking high-altitude stress has lacked comprehensive mechanistic validation. Our findings address this gap by demonstrating that SAL robustly alleviates CoCl2-induced myocardial injury through the preservation of mitochondrial homeostasis and partial restoration of the Akt/GSK-3β signaling balance. To establish this, we utilized CoCl2, which is widely employed as a chemical hypoxia-mimetic agent because it replicates key molecular hallmarks of hypoxic stress, including HIF-1α stabilization, redox imbalance, mitochondrial impairment, and apoptosis [30, 31]. In our study, CoCl2 exposure successfully induced a typical injury phenotype in H9C2 cells, marked by decreased viability, reactive oxygen species (ROS) accumulation, mitochondrial membrane potential (MMP) dissipation, and ATP depletion. Concurrently, CoCl2-treated rats exhibited electrocardiographic abnormalities, myocardial structural disruption, and cardiomyocyte hypertrophy. While these findings validate that our models captured the primary features of hypoxia-associated myocardial injury, it is important to note that CoCl2 exposure serves as a mimetic condition and cannot fully replicate the complex physiological responses triggered by true hypobaric hypoxia at high altitudes [21, 32, 33]. Within this pathophysiological framework, the most prominent biological effect of SAL was the attenuation of oxidative stress and the concurrent preservation of mitochondrial homeostasis. Oxidative stress in hypoxic cardiomyocytes is not merely a byproduct of cellular injury, but a critical upstream driver of mitochondrial destabilization and cell death [34, 35]. CoCl2 exposure markedly elevated intracellular ROS while suppressing the expression of key mitochondrial antioxidant enzymes, SOD2 and CAT. SAL treatment effectively reversed these changes, reducing ROS accumulation and restoring SOD2 and CAT expression, thereby enhancing intracellular redox-buffering capacity. Crucially, this antioxidant effect coincided with the recovery of MMP and ATP production. This suggests that SAL mitigates the functional consequences of mitochondrial injury rather than simply lowering oxidative readouts. By preventing energetic failure, a primary catalyst for cellular vulnerability under hypoxic stress, SAL robustly stabilizes mitochondrial function. Consequently, this stabilization directly impacts downstream cell survival. Excessive ROS and mitochondrial damage are well-known triggers of the intrinsic apoptotic pathway [22, 36, 37]. Consistent with this, CoCl2 increased the number of Hoechst- and Annexin V-positive cells, upregulated Bax, cleaved caspase-3, cleaved caspase-7, and cTnI, and downregulated Bcl2. SAL administration restored the Bcl2/Bax balance and attenuated apoptotic signaling. Therefore, the antiapoptotic effect of SAL should be viewed as a downstream benefit of improved mitochondrial resilience and reduced oxidative damage, a finding consistent with previous reports on its cardioprotective profile [17, 28, 29]. Against this background, the modulation of the Akt/GSK-3β signaling axis by SAL provides deeper mechanistic insight. Akt is a crucial stress-responsive kinase promoting cell survival, while GSK-3β is a downstream regulator of mitochondrial homeostasis and apoptosis, inhibited by phosphorylation at Ser9 [11, 20, 38, 39]. Our data indicate that CoCl2 disturbed the phosphorylation balance of this axis, increasing p-Akt (Ser473) while reducing p-GSK-3β (Ser9). Interestingly, SAL did not simply hyperactivate Akt beyond the CoCl2-induced state; rather, it normalized Akt levels while profoundly recovering the inhibitory phosphorylation of GSK-3β. The use of the selective Akt inhibitor MK-2206 further clarified this relationship [40]. Strikingly, while MK-2206 successfully and completely suppressed Akt phosphorylation, it did not attenuate the ability of SAL to promote the inhibitory phosphorylation of GSK-3β at Ser9, nor did it compromise SAL protective effects on Bcl2 and Bax. This compellingly indicates that the robust regulation of GSK-3β by SAL, and its subsequent anti-apoptotic effects, operate through a largely Akt-independent mechanism under hypoxia-mimetic conditions. Rather than relying solely on the linear Akt pathway, SAL likely targets GSK-3β directly or acts through a broader, parallel upstream kinase network to alleviate myocardial injury. Beyond the myocardium, SAL mitigated CoCl2-induced injury in the lungs and liver, highlighting its potential as a multiorgan protective agent against hypoxic damage. Clinically, severe high-altitude syndromes are frequently managed with broad-spectrum glucocorticoids, which modulate inflammation but can indirectly influence myocardial outcomes [41]. In contrast, SAL targets oxidative stress and mitochondrial dysfunction directly, offering a mechanistically distinct and complementary therapeutic approach. Furthermore, given its robust effects on redox homeostasis and cellular energetics, the protective scope of SAL may extend to other stress-associated myocardial injuries. For instance, subarachnoid hemorrhage-induced cardiomyopathy is similarly driven by catecholamine surges, oxidative injury, and mitochondrial impairment [42]. Although further validation in neurogenic models is necessary, these findings collectively underscore SAL as a promising multiorgan therapeutic strategy for high-altitude hypoxia and related systemic stresses. In conclusion, SAL effectively alleviates CoCl2-induced hypoxia-mimetic myocardial injury at both the cellular and tissue levels. Its cardioprotective effects are driven by the attenuation of oxidative stress, preservation of mitochondrial function, suppression of apoptosis, and the partial restoration of the Akt/GSK-3β signaling balance. Future studies utilizing physiologically relevant hypobaric hypoxia models, combined with direct target-verification strategies, will be essential to fully define the molecular basis and translational scope of SAL’s protective actions. Conclusion In summary, this study systematically demonstrates the robust cardioprotective efficacy of salidroside (SAL) against CoCl2-induced hypoxia-mimetic injury in both in vitro and in vivo models. Mechanistically, we reveal that SAL mitigates myocardial damage by attenuating oxidative stress, preserving mitochondrial homeostasis, suppressing apoptosis, and crucially, driving the protective inhibitory phosphorylation of GSK-3β through a largely Akt-independent mechanism. These findings not only refine our understanding of SAL’s pharmacological profile under hypoxic stress but also provide a compelling theoretical foundation for developing SAL-based therapeutics for hypoxia-related cardiovascular diseases. Future research utilizing physiologically relevant hypobaric hypoxia models and direct kinase target screening will be essential to fully elucidate the upstream regulators of this novel pathway and further expand SAL’s translational potential. Acknowledgments Author statement All the data were generated in-house, and no paper mill was used. All the authors agree to be accountable for all aspects of this work, ensuring its integrity and accuracy. Authors’ Contributions Yicheng Zhao and Lanzi Gongga: Conceptualization, writing-original draft. Danzeng Awang and Zong La: writing-review & editing, and visualization. Lanzi Gongga: Writing-review & editing, funding acquisition. Kangzhuo Baima: Validation. Hongjun Xie: Visualization. Li Wang: Conceptualization. Yueying Wang: Supervision, visualization. Xinyao Liu: Methodology, validation. Yan Shi: Supervision, funding acquisition. Funding This work was supported by a grant from the National Natural Science Foundation of China (No. U22A20340 and 81860567), the Key Research and Development Plan of the Tibet Autonomous Region Science and Technology Program (No. XZ202301ZY0011G), and the Natural Science Foundation of the Tibet Autonomous Region (No. XZ202001ZR0040G). The University Reform and Development—Funding for First-Class Discipline Construction: Capacity Building Program for Disciplines and Degree Programs—High altitude Medicine and Digital Intelligence (Grant No. Zangcai Yuzhi [2026] No. 1; Project No. 00061408), the Lhasa Major Science and Technology Program-Correlation Study between Iron and Diabetes Mellitus in High-Altitude Environment (Grant No. LSKJ202507). Data Availability All the data generated throughout this study can be obtained upon request from the corresponding authors. Declarations Ethics approval and consent to participate The animal experiments and surgical procedures were conducted in accordance with the guidelines established by the Institutional Animal Care and Use Committee of Jilin University School of Pharmaceutical Science and received ethical approval under number 20220030. Competing interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Danzeng Awang, Zong La and Kangzhuo Baima contributed equally to this work and share first authorship. Contributor Information Yan Shi, Email: shiyan@jlu.edu.cn. Yicheng Zhao, Email: yichengzhao@live.cn. Lanzi Gongga, Email: qeblanzi@utibet.edu.cn. References Associated Data Data Availability Statement All the data generated throughout this study can be obtained upon request from the corresponding authors.